VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the company to proceed with the PIONEER-ALS Phase… More >>

NeuroSense Therapeutics, a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational… More >>

Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig’s Disease (LGD) in the US, is a progressive neurodegenerative disease. Although relatively rare, with 2 new… More >>

Dear ALS/MND Community, We are writing to inform you that Ionis has completed enrollment of FUSION (NCT04768972), the pivotal Phase 3 clinical trial of our investigational medicine, ulefnersen (ION363). FUSION… More >>

• DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo • DAZALS met… More >>

Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves… More >>

Dear ALS community, We are pleased to share that Prilenia has entered into a collaboration and license agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and… More >>

TRICALS, in collaboration with King’s College London and Macquarie University, announced that the global Phase 3 placebo-controlled Lighthouse II study was terminated after the interim analysis did not demonstrate an… More >>